Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07562399 · ClinicalTrials.gov registry record · NA
Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda
A NA study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- NA
- Development phase
- 224
- Enrollment target
NCT07562399 is a NA study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 224 participants.
The verdict
NCT07562399, a NA study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 224 participants
- Enrollment target
Study Summary
This study aims to evaluate a multi-modal intervention designed to improve adherence to adjuvant endocrine therapy (AET) among patients with ER-positive breast cancer in Rwanda. The intervention includes educational, behavioral, and reminder components, and will be assessed for feasibility and impact on medication adherence.
Interventions
- BEHAVIORAL Educational video
- BEHAVIORAL Text reminders
- BEHAVIORAL Symptom monitoring card
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2026-09-20 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07562399
The ClinicalTrials.gov registry entry for NCT07562399 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Educational video is the first listed.
NCT07562399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07562399 about?
NCT07562399 is a clinical study titled "Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda". This study aims to evaluate a multi-modal intervention designed to improve adherence to adjuvant endocrine therapy (AET) among patients with ER-positive breast cancer in Rwanda. The intervention includes educational, behavioral, and reminder components, and will be assessed for feasibility and impac...
What is the current status of trial NCT07562399?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 224 participants. The study started on 2026-09-20. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07562399?
The interventions under investigation include: Educational video (BEHAVIORAL), Text reminders (BEHAVIORAL), Symptom monitoring card (BEHAVIORAL).
Who is sponsoring clinical trial NCT07562399?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.